$2.84 Billion in Sales Expected for Mylan NV (NASDAQ:MYL) This Quarter

Wall Street brokerages expect Mylan NV (NASDAQ:MYL) to post sales of $2.84 billion for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Mylan’s earnings, with estimates ranging from $2.75 billion to $2.90 billion. Mylan reported sales of $2.81 billion in the same quarter last year, which indicates a positive year over year growth rate of 1.1%. The company is expected to issue its next earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Mylan will report full year sales of $11.69 billion for the current year, with estimates ranging from $11.50 billion to $11.87 billion. For the next fiscal year, analysts forecast that the firm will report sales of $12.17 billion, with estimates ranging from $11.78 billion to $12.79 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Mylan.

Mylan (NASDAQ:MYL) last issued its earnings results on Tuesday, May 7th. The company reported $0.82 EPS for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.03. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The business had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.70 billion. During the same quarter last year, the firm posted $0.96 EPS. The business’s revenue for the quarter was down 7.0% compared to the same quarter last year.

Several research analysts have recently commented on MYL shares. SunTrust Banks started coverage on shares of Mylan in a report on Tuesday, March 19th. They issued a “buy” rating and a $35.00 price target for the company. Morgan Stanley set a $32.00 target price on shares of Mylan and gave the stock a “buy” rating in a report on Wednesday, May 8th. Raymond James set a $31.00 price objective on shares of Mylan and gave the company a “buy” rating in a research report on Wednesday, May 8th. Wells Fargo & Co cut shares of Mylan from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $33.00 to $22.00 in a research note on Tuesday, May 7th. Finally, BidaskClub upgraded shares of Mylan from a “sell” rating to a “hold” rating in a research note on Monday, May 6th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $34.15.

Several large investors have recently modified their holdings of the company. RPG Investment Advisory LLC grew its stake in shares of Mylan by 1.2% during the 2nd quarter. RPG Investment Advisory LLC now owns 214,812 shares of the company’s stock worth $4,113,000 after acquiring an additional 2,573 shares during the period. New Jersey Better Educational Savings Trust increased its position in shares of Mylan by 30.0% during the 2nd quarter. New Jersey Better Educational Savings Trust now owns 13,000 shares of the company’s stock valued at $248,000 after purchasing an additional 3,000 shares during the last quarter. Retirement Systems of Alabama increased its position in shares of Mylan by 121.2% during the 2nd quarter. Retirement Systems of Alabama now owns 531,186 shares of the company’s stock valued at $10,114,000 after purchasing an additional 291,086 shares during the last quarter. Supplemental Annuity Collective Trust of NJ increased its position in shares of Mylan by 60.0% during the 2nd quarter. Supplemental Annuity Collective Trust of NJ now owns 16,000 shares of the company’s stock valued at $305,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. increased its position in shares of Mylan by 16.9% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 522,095 shares of the company’s stock valued at $14,796,000 after purchasing an additional 75,655 shares during the last quarter. 83.71% of the stock is currently owned by institutional investors.

MYL traded down $0.49 during trading hours on Wednesday, reaching $19.13. 8,265,778 shares of the stock traded hands, compared to its average volume of 6,454,997. The business’s fifty day moving average price is $18.28. The firm has a market cap of $10.11 billion, a P/E ratio of 4.18, a price-to-earnings-growth ratio of 1.01 and a beta of 1.76. Mylan has a fifty-two week low of $16.63 and a fifty-two week high of $39.59. The company has a current ratio of 1.51, a quick ratio of 0.85 and a debt-to-equity ratio of 1.20.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Read More: Economic Reports

Get a free copy of the Zacks research report on Mylan (MYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.